Diverse microtubule-destabilizing drugs induce equivalent molecular pathway responses in endothelial cells.

ABSTRACT: Drugs that modulate microtubule (MT) dynamics are well-characterized at the molecular level, yet the mechanisms linking these molecular effects to their distinct clinical outcomes remain unclear. Several MT-destabilizing drugs, including vinblastine, combretastatin A4, and plinabulin, are widely used, or are under evaluation for cancer treatment. Although all three depolymerize MTs, they do so through distinct biochemical mechanisms. Furthermore, their clinical profiles and therapeutic uses differ considerably. To investigate whether differential modulation of molecular pathways might account for clinical differences, we compared gene expression and signaling pathway responses in human pulmonary microvascular endothelial cells (HPMECs), alongside the MT-stabilizing drug docetaxel and the p

SUBMITTER: Horin LJ 

PROVIDER: S-EPMC11785092 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature